Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia

Overview

Información sobre este estudio

The purpose of this study is to demonstrate that scar-based ventricular tachycardia (VT) ablation using the FlexAbility™ ablation catheter system results in a superior clinical outcome compared to routine drug therapy in subjects with documented Monomorphic Ventricular Tachycardia [MMVT] (both ischemic and non-ischemic) while maintaining an acceptable safety profile.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Patient is receiving a new St.Jude Medical (SJM) Implantable Cardioverter Defibrillator (ICD) or SJM Cardiac Resynchronization Therapy-Defibrillator (CRT-D) implant, which has study required programing capabilities and is appropriate for remote monitoring
  • Subjects who have received the ICD / CRT-D up to 90 days prior to enrollment are also eligible. 
  • Patient who has a high risk of ICD shock as shown by at least one documented Monomorphic VT (MMVT) by one or more of the following
    • Spontaneous MMVT 
    • Inducible MMVT during electrophysiology (EP) Study
    • Inducible MMVT during Non-Invasive Programmed Stimulation (NIPS) Study 
  • Pleiomorphic ventricular tachycardia (VT) (multiple MMVT morphologies) is acceptable but polymorphic VT or ventricular fibrillation (VF) is not.
  • 18 to 75 years of age 
  • Patient has been informed of the nature of the study and has agreed to its provisions and provided written informed consent approved by the Institutional Review Board 

 

Exclusion Criteria

  • Any history of stroke 
  • S-T elevation myocardial infarction (MI) or previous cardiac surgery within 60 days prior to enrollment 
  • Patient is pregnant or nursing 
  • Patient has New York Heart Association (NYHA) class IV heart failure 
  • Patient has incessant ventricular tachycardia (VT) necessitating immediate treatment.
    • Patients with Incessant VT have continuous sustained VTs that recur promptly despite repeated intervention for termination over several ( ≥ 3) hours
  • Patient has VT/ VF thought to be from channelopathies
  • Limited life expectancy (less than one year) according to Investigator 
  • Patient has current class IV angina 
  • Recent coronary artery bypass graft (CABG < 60 days) or percutaneous coronary intervention (PCI < 30 days) 
  • Patient is currently participating in another investigational drug or device study
  • Patient is unable or unwilling to cooperate with the study procedures 
  • Known presence of intracardiac thrombi (i.e., positive Transesophageal Echocardiogram (TEE) for LA or LV clot)
    • TEE is required for history of left atrium (LA) or left ventricle (LV) clot and recommended for history of atrial fibrillation (AF) with CHADS > 1 
  • Prosthetic mitral or aortic valve 
  • Mitral or aortic valvular heart disease requiring immediate surgical intervention 
  • Major contraindication to anticoagulation therapy or coagulation disorder 
  • Left Ventricular Ejection Fraction < 15%
  • Patient has had a previous ablation procedure for ventricular tachycardia (VT), excluding remote ( > 3 months) outflow tract tachycardia 
  • Patient has glomerular filtration rate (GFR) < 30 mL/min/1.73m2 within the past 3 months 
  • Patient has peripheral vascular disease that precludes LV access
  • Patient has a premature ventricular contraction (PVC) or VT induced cardiomyopathy that is expected to resolve with ablation and will not require an ICD 
  • Patient has reversible cause of VT
  • Use of left ventricular assist device (LVAD) or Tandem Heart devices (Impella and Balloon pumps are acceptable) 
  • There is a strong clinical reason to believe that, in the opinion of the investigator, the patient only has septal scar that is deep

More information

Publicaciones

Publications are currently not available
.
CLS-20154269

Mayo Clinic Footer